HIRA analyzes National Health Insurance claims data from 2021 to 2025

Patients aged 15 to 19 surge from around 21,000 to over 58,000

Seoul, Gyeonggi, and Busan account for two-thirds of claims

The number of adolescent patients prescribed methylphenidate, a medication used to treat attention-deficit/hyperactivity disorder (ADHD), has increased 2.8-fold over the past five years. By month, prescriptions peaked in August, during the summer vacation.


ADHD Drug? ... Adolescent Prescriptions for "Methylphenidate" Rise 2.8-Fold in 5 Years View original image

An analysis by the Health Insurance Review and Assessment Service (HIRA) of National Health Insurance claims data from 2021 to 2025 found that the number of adolescents aged 15 to 19 prescribed methylphenidate rose 2.8-fold, from 20,955 in 2021 to 58,174 in 2025.


Over the same period, the number of National Health Insurance claims for methylphenidate for adolescent patients increased 2.6-fold, from 170,984 to 440,641, while the total amount dispensed rose 2.7-fold, from approximately 5.95 million to 16.24 million. All three measures—the number of patients, claims, and total amount dispensed—grew faster than the corresponding figures for all age groups, which increased 2.5-fold, 2.4-fold, and 2.6-fold, respectively.


Among adolescents, prescription volume was highest in August and lowest in December. The seasonal indices for the number of patients, claims, and total amount dispensed all peaked in August and were lowest in December. The prescription seasonal index measures monthly differences while adjusting for the effect of annual growth trends; a reading above 100 means prescription volume was higher than usual.


Seoul and Gyeonggi Province accounted for large shares of claims. Based on the number of claims last year, Seoul accounted for 29.8% of the total and Gyeonggi Province for 25.4%. The three leading provinces and metropolitan cities, including Busan (10.9%), accounted for approximately 66% of claims. By district, the highest numbers of claims were recorded in Gangnam-gu and Songpa-gu in Seoul, Bundang-gu in Seongnam, Gyeonggi Province, Seocho-gu in Seoul, and Suseong-gu in Daegu, in that order.


ADHD Drug? ... Adolescent Prescriptions for "Methylphenidate" Rise 2.8-Fold in 5 Years View original image

A separate HIRA analysis of medications containing propranolol, for which prescriptions to adolescents have recently increased, found that the number of patients aged 15 to 19 prescribed the medication rose 1.5-fold, from 48,255 in 2021 to 70,507 in 2025. Claims also increased 1.4-fold over the same period, from 214,044 to 303,616. Monthly claims were highest in October and lowest in February.


Methylphenidate is often called a “study drug” or a “concentration-boosting drug.” Its misuse by people without ADHD to improve concentration or academic performance has been a longstanding concern. Propranolol is a beta blocker that lowers heart rate and blood pressure. It is used not only to treat hypertension and arrhythmia but also to prevent migraines and relieve tremors and palpitations caused by tension.


HIRA said the analysis reflects prescription patterns based on National Health Insurance claims data and does not assess the reasons for the increase in prescriptions, whether the medications were used appropriately, or whether patients actually took them. Prescriptions not covered by National Health Insurance were also excluded, and regional statistics were calculated based on the locations of medical institutions, not patients’ places of residence.



HIRA President Hong Seung-kwon said, “We hope this analysis will help people objectively understand prescription patterns among adolescents. We will continue to provide the public with the statistical information it needs through analyses using healthcare big data and support the safe use of medications.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing